SGR-1820

SGR-1820 is an orally bioavailable small molecule cytokine inhibitor currently in preclinical development by Schrodinger. It is being developed for the treatment of various inflammatory and immunological disorders. The drug was discovered and optimized using Schrodinger's proprietary physics-based computational platform, which allows for the precise modeling of molecular interactions to identify potent and selective small molecule candidates. While the specific cytokine target has not been publicly disclosed by the developer, the program aims to provide a convenient oral alternative to existing injectable biologic therapies that target similar immune signaling pathways. As of early 2024, the program remains in the preclinical stage of development.